Scp 791
Alternative Names: Scp-791Latest Information Update: 14 Feb 2023
At a glance
- Originator Silver Creek Pharmaceuticals
- Class Antiparkinsonians; Recombinant fusion proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 14 Feb 2023 Preclinical trials in Parkinson's disease in USA (Intrathecal) (before February 2023) (Silver Creek Pharmaceuticals Pipeline, February 2023)